106 related articles for article (PubMed ID: 3276397)
1. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397
[TBL] [Abstract][Full Text] [Related]
2. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
3. [Tumor markers--personal experience. Ha-ras P21 in neuroblastoma: a new marker associating to patient's prognosis].
Tanaka T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):143-50. PubMed ID: 1987897
[TBL] [Abstract][Full Text] [Related]
4. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
[TBL] [Abstract][Full Text] [Related]
5. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
[TBL] [Abstract][Full Text] [Related]
7. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis.
Tahara E; Yasui W; Taniyama K; Ochiai A; Yamamoto T; Nakajo S; Yamamoto M
Jpn J Cancer Res; 1986 Jun; 77(6):517-22. PubMed ID: 3089984
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein.
Krajewski S; Chatten J; Hanada M; Reed JC
Lab Invest; 1995 Jan; 72(1):42-54. PubMed ID: 7837790
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
[TBL] [Abstract][Full Text] [Related]
10. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Volm M; Mattern J
Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
[TBL] [Abstract][Full Text] [Related]
11. Ha-ras p21 in neuroblastoma: a new marker in prediction of patient outcome.
Tanaka T
Prog Clin Biol Res; 1994; 385():275-80. PubMed ID: 7972221
[No Abstract] [Full Text] [Related]
12. Relationship between ras oncogene expression and clinical and pathological features of colonic carcinoma.
Michelassi F; Grad G; Erroi F; Roncella M; Romagnoli J; Handcock M
Hepatogastroenterology; 1990 Oct; 37(5):513-6. PubMed ID: 2253930
[TBL] [Abstract][Full Text] [Related]
13. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study.
Tanaka T; Hiyama E; Sugimoto T; Sawada T; Tanabe M; Ida N
Cancer; 1995 Sep; 76(6):1086-95. PubMed ID: 8625212
[TBL] [Abstract][Full Text] [Related]
14. Ha-ras oncogene product in human oral squamous cell carcinoma.
Oku N; Shimada K; Itoh H
Kobe J Med Sci; 1989 Dec; 35(5-6):277-86. PubMed ID: 2699627
[TBL] [Abstract][Full Text] [Related]
15. Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma.
Yamamoto T; Hattori T; Tahara E
Pathol Res Pract; 1988 Nov; 183(6):663-9. PubMed ID: 3065747
[TBL] [Abstract][Full Text] [Related]
16. Optimal preservation of p21 ras immunoreactivity and morphology in paraffin-embedded tissue.
Going JJ; Williams AR; Wyllie AH; Anderson TJ; Piris J
J Pathol; 1988 Jul; 155(3):185-90. PubMed ID: 3045276
[TBL] [Abstract][Full Text] [Related]
17. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
18. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
Kumar S; Hand PH; Marsden HB; Kumar P; Thor A
Anticancer Res; 1991; 11(4):1657-62. PubMed ID: 1660693
[TBL] [Abstract][Full Text] [Related]
20. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
